Monopar TherapeuticsMNPR
Market Cap: $15.8M
About: Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
Employees: 12
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
15% more capital invested
Capital invested by funds: $269K [Q1] → $310K (+$41.5K) [Q2]
0.27% less ownership
Funds ownership: 2.66% [Q1] → 2.39% (-0.27%) [Q2]
25% less funds holding
Funds holding: 16 [Q1] → 12 (-4) [Q2]
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Sean Lee 55% 1-year accuracy 6 / 11 met price target | 34%upside $6 | Buy Maintained | 14 Aug 2024 |
Financial journalist opinion
Based on 3 articles about MNPR published over the past 30 days